The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

Martínez-Pinteño, Albert; Mezquida, Gisela; Bioque, Miquel; López-Ilundain, Jose M.; Andreu-Bernabeu, Álvaro; Zorrilla, Iñaki; Mané, Anna; Rodríguez‐Jiménez, Roberto; Corripio, Iluminada; Sarró, Salvador; Ibáñez, Ángela; Usall, Judith; Rivero, Olga; Gassó, Patricia; Leza, Juan C.; Cuesta, Manuel J.; Parellada, Mara; González‐Pinto, Ana; Berrocoso, Esther; Mas, Sergi; Bernardo, Miquel; Amoretti, Sílvia; Morén, Constanza; Urbiola, Elena; González-Peñas, Javier; Roldán, Alexandra; Catalán, Ana; González-Ortega, Itxaso; Toll, Alba; Legido, Teresa; Sánchez-Pastor, Luis; Dompablo, Mónica; Pomarol‐Clotet, Edith; Landín-Romero, Ramón; Butjosa, Anna; Rubio, Enrique Rodríguez; Lorente-OmeñacaR,; Ribeiro, Maria Helena; López-Torres, Isabel; León-Quismondo, Leticia; Nácher, Juan; Contretas, F; Lobò, Antonio; Gutiérrez-Fraile, Miguel; Villegas, P.

doi:10.1016/j.euroneuro.2022.02.003

Cited by 6 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of studies suggested that lower levels of BDNF relate to more severe symptoms [33,46,47]. It was reported that repeated BDNF serum level assessment can be useful in monitoring the effectiveness of neurorehabilitation, which improves social functioning among patients [48], whereas baseline values of BDNF can be valuable to assess the severity of negative schizophrenia symptoms; however, they are not associated with the risk of relapse [49,50].…”

Section: Bdnf In Schizophreniamentioning

confidence: 99%

“…Multiple meta-analyses showed that schizophrenia is associated with reduced peripheral NGF levels [63][64][65][66]. During the remission of the disease, lower NGF levels correlated with higher severity of negative symptoms [49]. NGF has also been associated with gray matter volume in specific regions of the brain of patients with schizophrenia [67].…”

Section: Ngf In Schizophreniamentioning

confidence: 99%

“…The baseline NGF level may also be an important marker of longterm disease severity, especially in terms of negative symptoms. However, measuring NGF levels is not helpful while assessing the risk of relapses [49]. Treatment of schizophrenia with NGF has not been pursued.…”

Section: Ngf In Schizophreniamentioning

confidence: 99%

See 2 more Smart Citations

Neuroprotective factors in schizophrenia: BDNF, NGF, NT3, GDNF and their connection to the pathogenesis of schizophrenia. A narrative review

Sikorski

SIKORSKA²,

Michalska

et al. 2023

Curr Probl Psychiatry

View full text Add to dashboard Cite

Introduction: There are several hypotheses of schizophrenia pathogenesis, including the neurodegenerative theory, which is supported by evidence for the decrease of neuroprotective factors’ serum levels. The proteins, that exert a protective effect on neurons and are researched concerning schizophrenia pathogenesis, include the brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT3), and glial cell line-derived neurotrophic factor (GDNF). This review aims to discuss the role of neuroprotective factors in the development of schizophrenia and their relevance in clinical trials. Material and methods: This review was performed by search of the PubMed, Google Scholar, and Science Direct databases from December 25th, 2022, through January 31st, 2023, using keywords: ‘schizophrenia’, ‘schizophrenia pathogenesis’, ‘neuroprotection’, ‘neurodegeneration’, ‘BDNF’, ‘NGF’, ‘NT3’, and ‘GDNF’. We considered original research papers and systematic reviews published in English or Polish. Additionally, clinical trials, which included the assessment of neuroprotective factors’ levels in schizophrenia as outcome measures, were searched for on clinicaltrials.gov. Results: Lower levels of serum BDNF have been linked to cognitive impairment in schizophrenia. In clinical trials, the assessment of serum BDNF is used as a clinical outcome measure for novel schizophrenia therapies. Schizophrenia has also been associated with reduced peripheral NGF levels. During remission, lower NGF levels correlate with higher severity of negative symptoms. Decreased NT3 and GDNF levels can also be seen, but literature reports are inconsistent. Conclusions: Neuroprotective factors are most likely related to the pathogenesis of schizophrenia. Assessing the serum level of these proteins may prove to be an invaluable element of schizophrenia management. Keywords: schizophrenia, brain-derived neurotrophic factor, nerve growth factor,neurotrophin 3, glial cell line-derived neurotrophic factor

show abstract